摘要:
Disclosed are bGH and hGH analogs having the activity of the respective naturally occurring substances and a similar amino acid sequence varying from the sequence of the respective naturally occurring substances. Further there are disclosed pharmaceutical and veterinary compositions containing said analogs as well as methods for producing and purifying said analogs.
摘要:
Disclosed are bGH and hGH analogs having the activity of the respective naturally occurring substances and a similar amino acid sequence varying from the sequence of the respective naturally occurring substances. Further there are disclosed pharmaceutical and veterinary compositions containing said analogs as well as methods for producing and purifying said analogs.
摘要:
An improved vector which upon introduction into a suitable host containing the thermolabile repressor C 1 renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P L O L from lambda bacteriophage; the N utilization site; a first restriction enzyme site which follows thereafter; a ribosomal binding site; an ATG Initiation codon or DNA which is converted Into an ATG initiation codon upon insertion of the desired gene into the vector, a second restriction enzme site for inserting the gene in phase with the ATG initiation codon; an origin of replication and either a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present In the host or a fragment designated ci 434 which includes the gene for the cl 343 repressor protein and its associated promoter and operator. The distance between the 3' end of P L O L and the 5' end of the N utilization site is less than about 80 base pairs. The distance between the 3' end of the N utilization site and the 5' end of the ribosomal binding site is less than about 300 base pairs. Vectors of the invention may also include a T,T 2 rRNA transcription termination sequence located 3' of the second restriction enzyme site. The inventive vectors may have origin of replications capable of autonomous production in the host of at least 400 constitutive copies. Plasmids have been constructed from the vectors and used to produce bovine, chicken, porcine and human growth hormones. human apolipoprotein E and human superoxide dismutase and ana- loges thereof In host cells. Such superoxide dismutase or analogs thereof may be used to catalyze the reduction of superoxide radicais, reduce reperfusion injury, prolong the survival time of isolated organs and prevent neurological InJury. Enzymatically active eucaryotic superoxide dismutase or an analog thereof may also be produced by an improved method of this invention which employs a production medium having a concentration of Cu ++ greater than about about 2 ppm. . The invention also concerns improved methods of ro- covering purified enzymatically active eucaryotic superoxide dismutase or analogs thereof.
摘要:
An improved vector which upon introduction into a suitable host containing the thermolabile repressor C I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P L O L from lambda bacteriophage; the N utilization site; a first restriction enzyme site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzme site for inserting the gene in phase with the ATG initiation codon; an origin of replication and either a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host or a fragment designated cI⁴³⁴ which includes the gene for the cI⁴³⁴ repressor protein and its associated promoter and operator. The distance between the 3' end of P L O L and the 5' end of the N utilization site is less than about 80 base pairs. The distance between the 3' end of the N utilization site and the 5' end of the ribosomal binding site is less than about 300 base pairs. Vectors of the invention may also include a T₁T₂ rRNA transcription termination sequence located 3' of the second restriction enzyme site. The inventive vectors may have origin of replications capable of autonomous production in the host of at least 400 constitutive copies. Plasmids have been constructed from the vectors and used to produce bovine, chicken, porcine and human growth hormones, human apolipoprotein E and human superoxide dismutase and analogs thereof in host cells. Such superoxide dismutase or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs and prevent neurological injury. Enzymatically active eucaryotic superoxide dismutase or an analog thereof may also be produced by an improved method of this invention which employs a production medium having a concentration of Cu⁺⁺ greater than about about 2ppm. The invention also concerns improved methods of recovering purified enzymatically active eucaryotic superoxide dismutase or analogs thereof.
摘要:
An improved vector which upon introduction into a suitable host containing the thermolabile repressor C I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P L O L from lambda bacteriophage; the N utilization site; a first restriction enzyme site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzme site for inserting the gene in phase with the ATG initiation codon; an origin of replication and either a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host or a fragment designated cI⁴³⁴ which includes the gene for the cI⁴³⁴ repressor protein and its associated promoter and operator. The distance between the 3' end of P L O L and the 5' end of the N utilization site is less than about 80 base pairs. The distance between the 3' end of the N utilization site and the 5' end of the ribosomal binding site is less than about 300 base pairs. Vectors of the invention may also include a T₁T₂ rRNA transcription termination sequence located 3' of the second restriction enzyme site. The inventive vectors may have origin of replications capable of autonomous production in the host of at least 400 constitutive copies. Plasmids have been constructed from the vectors and used to produce bovine, chicken, porcine and human growth hormones, human apolipoprotein E and human superoxide dismutase and analogs thereof in host cells. Such superoxide dismutase or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of isolated organs and prevent neurological injury. Enzymatically active eucaryotic superoxide dismutase or an analog thereof may also be produced by an improved method of this invention which employs a production medium having a concentration of Cu⁺⁺ greater than about about 2ppm. The invention also concerns improved methods of recovering purified enzymatically active eucaryotic superoxide dismutase or analogs thereof.
摘要:
Disclosed is an improved plasmid which upon introduction into a suitable Escherichia coli host cell containing the thermolabile repressor C I , renders the host cell capable, upon increasing the temperature of the host cell to a temerature at which the repressor is destroyed, of effecting expression of a gene encoding superoxide dismutase inserted into the vector, and production of the superoxide dismutase encoded by the gene.
摘要:
L'invention concerne des plasmides d'expression bactérienne de polypeptides comprenant une partie substantielle de la séquence d'acides aminés, et présentant l'activité biologique, d'un des domaines de fibronectine humaine se produisant naturellement, tel que le domaine de liaison de cellules ou le domaine de liaison de fibrine, comprenant de l'ADN codant le polypeptide et de l'ADN codant des éléments régulateurs adaptés positionnés par rapport à lADN codant le polypeptide, de manière à procéder à l'expression du polypeptide dans une cellule hôte adéquate. Dans le mode de réalisation actuellement préféré de l'invention, le polypeptide est un polypeptide 75 kD, 40 kD ou 33 kD du domaine de liaison de cellules, ou un polypeptide 31 kD ou un 20 kD du domaine de liaison de fibrine. L'invention concerne également des procédés de production des polypeptides ainsi que des compositions pharmaceutiques les comprenant et des supports pharmaceutiquement acceptables. On peut utiliser les polypeptides de l'invention afin d'inhiber l'agrégation de plaquettes, d'inhiber la libération de thromboxane par les plaquettes, ou afin de traiter un sujet atteint de troubles cérébrovasculaires, de troubles cardiovasculaires, souffrant d'une blessure, d'une infection bactérienne, d'un cancer ou afin de détecter un thrombi de fibrine. L'invention concerne en outre les polypeptides conjugués à des agents thrombolytiques, des facteurs de croissance, de l'albumine de sérum, des facteurs sanguins ou du polyéthylène-glycol.